Gendie E. Lash
Queen's University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gendie E. Lash.
Journal of Biological Chemistry | 2002
Lynne-Marie Postovit; Michael A. Adams; Gendie E. Lash; Jeremy P. W. Heaton; Charles H. Graham
Tumor hypoxia is associated with a poor prognosis for patients with various cancers, often resulting in an increase in metastasis. Moreover, exposure to hypoxia increases the ability of breast carcinoma cells to invade the extracellular matrix, an important aspect of metastasis. Here, we demonstrate that the hypoxic up-regulation of invasiveness is linked to reduced nitric oxide signaling. Incubation of human breast carcinoma cells in 0.5% versus 20% oxygen increased their in vitro invasiveness and their expression of the urokinase receptor, an invasion-associated molecule. These effects of hypoxia were inhibited by nitric oxide-mimetic drugs; and in a manner similar to hypoxia, pharmacological inhibition of nitric oxide synthesis increased urokinase receptor expression. The nitric oxide signaling pathway involves activation of soluble guanylyl cyclase (sGC) and the subsequent activation of protein kinase G (PKG). Culture of tumor cells under hypoxic conditions (0.5% versus 20% oxygen) resulted in lower cGMP levels, an effect that could be prevented by incubation with glyceryl trinitrate. Inhibition of sGC activity with a selective blocker or with the heme biosynthesis inhibitor desferrioxamine increased urokinase receptor expression. These compounds also prevented the glyceryl trinitrate-mediated suppression of urokinase receptor expression in cells incubated under hypoxic conditions. In contrast, direct activation of PKG using 8-bromo-cGMP prevented the hypoxia- and desferrioxamine-induced increases in urokinase receptor expression as well as the hypoxia-mediated enhanced invasiveness. Further involvement of PKG in the regulation of invasion-associated phenotypes was established using a selective PKG inhibitor, which alone increased urokinase receptor expression. These findings reveal that an important mechanism by which hypoxia increases tumor cell invasiveness (and possibly metastasis) requires inhibition of the nitric oxide signaling pathway involving sGC and PKG activation.
International Journal of Cancer | 2004
Lynne-Marie Postovit; Michael A. Adams; Gendie E. Lash; Jeremy P. W. Heaton; Charles H. Graham
Tumour hypoxia is associated with resistance to therapy and with increased invasion and metastatic potential. Recent studies in our laboratory have shown that the hypoxic up‐regulation of tumour cell invasiveness and chemoresistance is in part due to reduced nitric oxide (NO) signaling. Using B16F10 murine melanoma cells, we demonstrate here that the increased metastatic potential associated with exposure to hypoxia is mediated by a reduction in cGMP‐dependent NO‐signaling. Pre‐incubation of B16F10 cells in hypoxia (1% vs. 20% O2) for 12 hr increased lung colonization ability by over 4‐fold. This effect of hypoxia on metastasis was inhibited by co‐incubation with low concentrations of the NO‐mimetic drugs glyceryl trinitrate (GTN) and diethylenetriamine NO adduct (DETA/NO). In a manner similar to hypoxia, pharmacological inhibition of NO synthesis resulted in a significant increase in lung nodule formation, an effect that was prevented by co‐incubation with GTN. An important NO‐signaling pathway involves the activation of soluble guanylyl cyclase and the consequential generation of cGMP. Culture in the presence of a non‐hydrolysable cGMP analogue (8‐Br‐cGMP) abrogated the hypoxia‐induced lung nodule formation, suggesting that the effects of NO on metastasis are mediated via a cGMP‐dependent pathway. These findings suggest that a novel mechanism whereby hypoxia regulates metastatic potential involves a downstream inhibition of cGMP‐dependent NO signaling.
Experimental Cell Research | 2003
Tania E. Fitzpatrick; Gendie E. Lash; Atsushi Yanaihara; D. Stephen Charnock-Jones; Shannyn K. Macdonald-Goodfellow; Charles H. Graham
Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen and angiogenic growth factor that enhances endothelial cell invasion through the extracellular matrix (ECM). While various cell types express VEGF receptors, little is known about the biological actions of VEGF on nonendothelial cells. Therefore, the main objective of the present study was to determine the effect of VEGF on the in vitro invasiveness and proliferation of human MDA-MB-231 breast carcinoma cells and human HTR-8/SVneo trophoblast cells. Reverse-transcriptase polymerase chain reaction analysis demonstrated the presence of transcripts encoding VEGF receptors (VEGFR) -1, -2, and -3 as well as neuropilins-1 and -2 in the trophoblast cells, and the presence of transcripts encoding VEGFR-2 and neuropilins-1 and -2 in the breast carcinoma cells. Both cell lines also expressed transcripts for VEGF-A, -B, -C and -D, as well as for placenta growth factor (PlGF). Although incubation with exogenous VEGF-A(165) or VEGF-A(121) did not affect the rate of proliferation of either the trophoblast or the breast carcinoma cells, incubation with these molecules reduced their ability to invade through reconstituted ECM (Matrigel). The effect of VEGF-A(165) on the invasiveness of both cell lines was inhibited by the inclusion of a neutralizing antibody to VEGF. Exogenous VEGF-A(165) also decreased the cell surface expression of the urokinase-type plasminogen activator (a molecule required for invasion) by the breast carcinoma and trophoblast cells. These results indicate that the biological actions of VEGF on certain cell types may differ from the effects of this molecule on vascular endothelial cells, and therefore are relevant to angiogenesis-based therapies.
Experimental Biology and Medicine | 2003
Brian E. McLaughlin; Gendie E. Lash; Graeme N. Smith; Gerald S. Marks; Kanji Nakatsu; Charles H. Graham; James F. Brien
Carbon monoxide (CO), formed during heme oxygenase (HO)-catalyzed oxidation of heme, has been proposed to play a complementary role with nitric oxide in the regulation of placental hemodynamics. The objective of this study was to elucidate HO enzymatic activity and HO-1 (inducible) and HO-2 (constitutive) protein content in the microsomal subcellular fraction of homogenate of selected regions of placenta from normotensive and mild pre-eclamptic pregnancies. HO enzymatic activity was measured under optimized conditions by gas chromatography using CO formation as an index of activity, and HO-1 and HO-2 protein content were determined by Western immunoblot analysis. Microsomal HO activity in each of the four placental regions was not different between normotensive and mild pre-eclamptic pregnancies. Microsomal HO-2 protein content was not different between normotensive and mild pre-eclamptic pregnancies, whereas there was increased expression of microsomal HO-1 protein in chorionic villi and fetal membranes from pre-eclamptic pregnancy compared with normotensive pregnancy. Microsomal HO enzymatic activity correlated with HO-2, but not HO-1, protein content.
Best Practice & Research in Clinical Obstetrics & Gynaecology | 2000
Stephen Ong; Gendie E. Lash; P.N. Baker
American Journal of Physiology-heart and Circulatory Physiology | 2003
Gendie E. Lash; Brian E. McLaughlin; S. K. MacDonald-Goodfellow; Graeme N. Smith; James F. Brien; Gerald S. Marks; Kanji Nakatsu; Charles H. Graham
Biochemical and Biophysical Research Communications | 2001
Gendie E. Lash; Tania E. Fitzpatrick; Charles H. Graham
Molecular Human Reproduction | 2001
Gendie E. Lash; Anne M. Macpherson; David Liu; Donna Smith; Steven Charnock-Jones; Philip N. Baker
The Journal of Clinical Endocrinology and Metabolism | 2005
Louiza Belkacemi; Gendie E. Lash; Shannyn K. Macdonald-Goodfellow; Jason D. Caldwell; Charles H. Graham
American Journal of Physiology-heart and Circulatory Physiology | 2003
Scott D. Appleton; Gerald S. Marks; Kanji Nakatsu; James F. Brien; Graeme N. Smith; Charles H. Graham; Gendie E. Lash